Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Cancer
NCT04296890Phase 3Completed
- Sponsor
- ImmunoGen
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of mirvetuximab soravtansine in Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by ImmunoGen. Primary endpoint: Objective Response Rate at 15 months. Started Jul 2020; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04296890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296890.